IVIG for Infection Prevention After CAR-T-Cell Therapy
Condition: Lymphoma Interventions: Biological: Immune Globulin Infusion (Human), 10% Solution; Biological: Anti-CD19-targeting CAR-T Cells; Other: Saline; Procedure: Biospecimen Collection; Other: Survey Administration; Other: Electronic Health Record Review Sponsors: Fred Hutchinson Cancer Center; Takeda; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials